Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
Fiche publication
Date publication
janvier 2018
Journal
Rheumatology (Oxford, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GOTTENBERG Jacques-Eric
Tous les auteurs :
Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE,
Lien Pubmed
Résumé
The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics.
Mots clés
Abatacept, adverse effects, Adult, Aged, Anaphylaxis, chemically induced, Antibodies, Monoclonal, Humanized, adverse effects, Antirheumatic Agents, adverse effects, Arthritis, Rheumatoid, drug therapy, Drug Eruptions, epidemiology, Female, Humans, Hypertension, chemically induced, Infusions, Intravenous, Logistic Models, Male, Middle Aged, Multivariate Analysis, Peptides, Cyclic, immunology, Pharyngitis, chemically induced, Registries, Risk Factors, Rituximab, adverse effects, Severity of Illness Index
Référence
Rheumatology (Oxford). 2018 01 1;57(1):134-139